| 000 | 01575 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513144514.0 | ||
| 264 | 0 | _c19980702 | |
| 008 | 199807s 0 0 eng d | ||
| 022 | _a0284-186X | ||
| 024 | 7 |
_a10.1080/028418698429757 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarles, J | |
| 245 | 0 | 0 |
_aPhase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. _h[electronic resource] |
| 260 |
_bActa oncologica (Stockholm, Sweden) _c1998 |
||
| 300 |
_a187-91 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEstramustine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 650 | 0 | 4 | _aVinorelbine |
| 700 | 1 | _aDomenech, M | |
| 700 | 1 | _aGelabert-Mas, A | |
| 700 | 1 | _aNogue, M | |
| 700 | 1 | _aTabernero, J M | |
| 700 | 1 | _aArcusa, A | |
| 700 | 1 | _aGuasch, I | |
| 700 | 1 | _aMiguel, A | |
| 700 | 1 | _aBallesteros, J J | |
| 700 | 1 | _aFabregat, X | |
| 773 | 0 |
_tActa oncologica (Stockholm, Sweden) _gvol. 37 _gno. 2 _gp. 187-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/028418698429757 _zAvailable from publisher's website |
| 999 |
_c9602296 _d9602296 |
||